Genfit SA 주요 수익원은 Innovative Medicines and Diagnostic Solutions이며, 최신 수익 발표에서 수익은 67,001,999입니다. 지역별로는 France이 Genfit SA의 주요 시장이며, 수익은 67,001,999입니다.
Genfit SA은 수익성이 있나요?
예, 최신 재무제표에 따르면 Genfit SA의 순이익은 $1입니다.
Genfit SA에 부채가 있나요?
예, Genfit SA의 부채는 82입니다.
Genfit SA의 발행 주식은 몇 주인가요?
Genfit SA의 총 발행 주식은 49.99주입니다.
주요 통계
이전 종가
$8.6
시가
$9
일일 범위
$8.85 - $9
52주 범위
$2.55 - $8.95
거래량
4.2K
평균 거래량
9.8K
배당수익률
--
EPS(TTM)
-0.90
시가총액
$447.5M
GNFT란 무엇인가요?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.